Home > Company News
News Category

Fanzhi Pharmaceutical passed the GMP certification of "Monoammonium Glycyrrhizinate S"

Views : 94
Update time : 2020-02-10 08:23:00
The evaluation and certification center of Gansu drug administration appointed a GMP certification expert group to conduct on-site inspection on the implementation of GMP by Gansu Fanzhi Pharmaceutical Co., Ltd. from December 7 to 8, 2019.
10246586

The scope of applying for GMP certification of Pan plant pharmaceutical is: the production line of API "Monoammonium Glycyrrhizinate S".
微信图片_20200210151832

During the inspection, the expert group conducted communication, inspection and evaluation on the quality management system, organizational structure, personnel training, plant facilities, material management, production management, quality management, verification and confirmation, product shipment and recall, document system and other aspects of Gansu Fanzhi pharmaceutical in a serious and responsible manner.

After the on-site inspection and review of the rectification report, the publicity ended on January 16, 2020, and Gansu provincial drug and Food Administration issued a formal notice on February 3, 2020, which showed that the GMP inspection results: the GMP certification of "Monoammonium Glycyrrhizinate S" applied by Gansu Fanzhi Pharmaceutical Co., Ltd. was in line with the code for the quality management of drug production (revised in 2010).
泛植制药工厂
Gansu Fanzhi Pharmaceutical Co., Ltd. has long controlled the product quality with high standard quality requirements, which has attracted the attention of the industry. The "Monoammonium Glycyrrhizinate S" GMP on-site certification inspection was successfully completed, which laid a solid foundation for future development. New and old customers are welcome to inquire and Book products.